Johnson-Levonas AO - Search Results

1

A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.

Tatosian DA, Cardillo Marricco N, Glasgow XS, DeGroot B, Dunnington K, George L, Gendrano IN, Johnson-Levonas AO, Swearingen D, Kauh E. Tatosian DA, et al. Among authors: johnson levonas ao. Clin Pharmacol Drug Dev. 2016 Sep;5(5):383-92. doi: 10.1002/cpdd.260. Epub 2016 Apr 29. Clin Pharmacol Drug Dev. 2016. PMID: 27627194 Clinical Trial.

2

Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.

Addy C, Tatosian D, Glasgow XS, Gendrano IN 3rd, Kauh E, Martucci A, Johnson-Levonas AO, Selverian D, Matthews CZ, Gutierrez M, Wagner JA, Aubrey Stoch S. Addy C, et al. Clin Ther. 2016 Mar;38(3):516-30. doi: 10.1016/j.clinthera.2015.12.020. Epub 2016 Feb 9. Clin Ther. 2016. PMID: 26869191 Clinical Trial.

3

Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects.

Krishna R, Addy C, Tatosian D, Glasgow XS, Gendrano Iii IN, Robberechts M, Haazen W, de Hoon JN, Depré M, Martucci A, Peng JZ, Johnson-Levonas AO, Wagner JA, Stoch SA. Krishna R, et al. J Clin Pharmacol. 2016 Dec;56(12):1528-1537. doi: 10.1002/jcph.773. Epub 2016 Jun 17. J Clin Pharmacol. 2016. PMID: 27225334 Free PMC article. Clinical Trial.

4

Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers.

Lauring B, Liu Y, Li XS, Larson P, Moreau A, Farmer HF, Johnson-Levonas AO, Wagner JA, Lai E. Lauring B, et al. J Clin Pharmacol. 2014 Jul;54(7):765-75. doi: 10.1002/jcph.278. Epub 2014 Mar 6. J Clin Pharmacol. 2014. PMID: 24615657 Clinical Trial.

5

Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.

Wright DH, Herman GA, Maes A, Liu Q, Johnson-Levonas AO, Wagner JA. Wright DH, et al. J Clin Pharmacol. 2009 Oct;49(10):1157-67. doi: 10.1177/0091270009341653. J Clin Pharmacol. 2009. PMID: 19783710 Clinical Trial.

6

Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers.

Luo WL, Crumley T, Ebel D, Atiee GJ, Royalty J, Johnson-Levonas AO, Wagner J, Lai E. Luo WL, et al. J Clin Pharmacol. 2010 Nov;50(11):1273-9. doi: 10.1177/0091270009360042. Epub 2010 Jan 27. J Clin Pharmacol. 2010. PMID: 20107202 Clinical Trial.

7

Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the steady-state pharmacokinetics of digoxin in healthy adult subjects.

Liu F, Vessey L, Wenning L, Connolly S, Buckland M, Johnson-Levonas AO, Denker A, Wagner JA, Lai E. Liu F, et al. J Clin Pharmacol. 2010 Jul;50(7):823-8. doi: 10.1177/0091270009356571. Epub 2010 Mar 2. J Clin Pharmacol. 2010. PMID: 20197486 Clinical Trial.

8

Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler device.

Kosoglou T, Hubbell J, Johnson-Levonas AO, Yunan M, Kantesaria BS, Cutler DL. Kosoglou T, et al. Clin Pharmacol Drug Dev. 2014 May;3(3):222-8. doi: 10.1002/cpdd.94. Epub 2014 Feb 18. Clin Pharmacol Drug Dev. 2014. PMID: 27128612 Clinical Trial.

9

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not affect the pharmacokinetics of ethinyl estradiol or norethindrone in healthy female subjects.

Migoya E, Larson P, Bergman A, Miller J, Johnson-Levonas AO, Lasseter KC, Wagner JA. Migoya E, et al. J Clin Pharmacol. 2011 Sep;51(9):1319-25. doi: 10.1177/0091270010381497. Epub 2011 Jan 5. J Clin Pharmacol. 2011. PMID: 21209231 Clinical Trial.

10

The Absence of a Clinically Significant Effect of Food on the Single Dose Pharmacokinetics of Vorapaxar, a PAR-1 Antagonist, in Healthy Adult Subjects.

Behm MO, Kosoglou T, Miltenburg AM, Li J, Statkevich P, Johnson-Levonas AO, Martinho M, Fackler P. Behm MO, et al. Clin Pharmacol Drug Dev. 2013 Oct;2(4):310-5. doi: 10.1002/cpdd.38. Clin Pharmacol Drug Dev. 2013. PMID: 27121935

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

91 results

Search Page

Filters